The Gene Therapy Innovation Showcase is organized by the OIS community. This event will provide a market overview complete with a start-up spotlight and followed with a deep-dive discussion complete with a panel of OD and MD KOLs. They will discuss the viability of products and share unique outlooks on the Gene Therapy sector of eye care.

Dr Magali Taiel, Chief Medical Officer, will present GenSight and its latest news about our most advanced product called LUMEVOQ® (GS010; lenadogene nolparvovec), a gene therapy targeting Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease leading to blindness in young adults. The LUMEVOQ® MAA was filed in September 2020 and is currently in the review phase of its registration process in Europe. The EMA decision is expected in Q4 2021.

You can register for free at the following link: